A detailed history of Arrowstreet Capital, Limited Partnership transactions in Exelixis, Inc. stock. As of the latest transaction made, Arrowstreet Capital, Limited Partnership holds 421,467 shares of EXEL stock, worth $9.47 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
421,467
Previous 79,464 430.39%
Holding current value
$9.47 Million
Previous $1.91 Million 424.71%
% of portfolio
0.01%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$20.17 - $23.93 $6.9 Million - $8.18 Million
342,003 Added 430.39%
421,467 $10 Million
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $1.53 Million - $1.92 Million
79,464 New
79,464 $1.91 Million
Q4 2022

Feb 14, 2023

BUY
$14.96 - $17.39 $2.29 Million - $2.66 Million
152,977 Added 100.9%
304,590 $4.89 Million
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $12.4 Million - $17.6 Million
-791,142 Reduced 83.92%
151,613 $2.38 Million
Q2 2022

Aug 15, 2022

BUY
$17.44 - $23.16 $16.4 Million - $21.8 Million
942,755 New
942,755 $19.6 Million
Q1 2022

May 13, 2022

SELL
$17.03 - $22.67 $12.5 Million - $16.6 Million
-732,860 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$15.84 - $21.88 $7.61 Million - $10.5 Million
480,418 Added 190.31%
732,860 $13.4 Million
Q3 2021

Nov 12, 2021

BUY
$16.3 - $21.14 $3.69 Million - $4.79 Million
226,637 Added 878.27%
252,442 $5.34 Million
Q2 2021

Aug 13, 2021

BUY
$17.95 - $25.56 $463,199 - $659,575
25,805 New
25,805 $470,000
Q1 2021

May 14, 2021

SELL
$20.53 - $25.22 $14.8 Million - $18.2 Million
-721,933 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$18.39 - $24.8 $12.5 Million - $16.9 Million
681,606 Added 1690.2%
721,933 $14.5 Million
Q3 2020

Nov 12, 2020

SELL
$20.67 - $26.94 $6.99 Million - $9.11 Million
-338,118 Reduced 89.34%
40,327 $986,000
Q2 2020

Aug 12, 2020

BUY
$16.46 - $27.42 $6.23 Million - $10.4 Million
378,445 New
378,445 $8.98 Million
Q1 2020

May 15, 2020

SELL
$14.46 - $21.8 $25.1 Million - $37.9 Million
-1,738,541 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$15.15 - $18.89 $25.1 Million - $31.2 Million
1,654,141 Added 1959.88%
1,738,541 $30.6 Million
Q3 2019

Nov 14, 2019

BUY
$17.68 - $22.65 $1.49 Million - $1.91 Million
84,400 New
84,400 $1.49 Million
Q2 2019

Aug 14, 2019

SELL
$18.93 - $24.75 $842,385 - $1.1 Million
-44,500 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$19.6 - $24.76 $872,200 - $1.1 Million
44,500 New
44,500 $1.06 Million
Q2 2018

Aug 14, 2018

SELL
$18.56 - $22.45 $39.3 Million - $47.6 Million
-2,119,065 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$22.15 - $31.89 $6.11 Million - $8.8 Million
275,936 Added 14.97%
2,119,065 $46.9 Million
Q4 2017

Feb 09, 2018

BUY
$24.23 - $30.93 $11.4 Million - $14.6 Million
471,023 Added 34.33%
1,843,129 $56 Million
Q3 2017

Nov 14, 2017

BUY
$23.35 - $29.24 $32 Million - $40.1 Million
1,372,106
1,372,106 $33.2 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $7.23B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Arrowstreet Capital, Limited Partnership Portfolio

Follow Arrowstreet Capital, Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.